Antipsychotic medications: Compliance and attitudes towards treatment

Current Opinion in Psychiatry

Volumn 17, Issue 2, 2004, Pages 75-80

  Awad, A George ^a,b  

^a HUMBER RIVER REGIONAL HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Adherence; Adherence therapy; Antipsychotic medications; Attitudes towards treatment; Schizophrenia

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CLOZAPINE; NEUROLEPTIC AGENT;

AKATHISIA; BEHAVIOR THERAPY; CLINICAL TRIAL; DATA ANALYSIS; DIABETES MELLITUS; DOSE RESPONSE; DRUG TOLERABILITY; DYSPHORIA; ECONOMIC ASPECT; EVALUATION; EXTRAPYRAMIDAL SYMPTOM; FAMILY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; META ANALYSIS; METHODOLOGY; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT EDUCATION; PREVALENCE; RELAPSE; REVIEW; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 1542329000     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001504-200403000-00002     Document Type: Review

References (41)

1. Awad AG. Antipsychotic medications in schizophrenia: how satisfied are our patients? In: Hellwell J, editor. Clear perspectives - management issues in schizophrenia: patient satisfaction, compliance and outcomes in schizophrenia. United Kingdom: Shire Hall International; 1999. pp. 1-6.
2. Awad AG, Voruganti LNP, Heslegrave RJ. The aims of antipsychotic medications: what are they and are they being achieved? CNS Drugs 1995; 4:8-16.
3. Van Putten T, May DRA, Marder SR. Subjective response to antipsychotic drugs. Arch Gen Psychiatry 1981; 38:187-190.
4. Awad AG. Subjective response to neuroleptics in schizophrenia. Schizophr Bull 1993; 19:609-618.
5. Weiden PI, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995; 21:419-429.
6. Awad AG, Masty V, McDonnell D. The link between drug attitudes, compliance behaviours and resource use among individuals with schizophrenia [abstract]. The 152nd Annual Meeting of the American Psychiatric Association; 15-20 May 1999; Washington, D.C.; (Book of Abstracts); p. 139.
7. Haynes RB, Taylor DW, Sachett DL. Compliance in health care. Baltimore: Johns Hopkins University Press; 1979.
8. Breen R, Thornhill JT. Noncompliance with medications for psychiatric disorders: reasons and remedies. CNS Drugs 1998; 9:457-471.
9. Baldessarini R. Enhancing treatment with psychotropic medications. Bull Menninger Clin 1994; 58:224-241.
10. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997; 23:637-651.
11. Perkins DO. Adherence to antipsychotic medications. J Clin Psychiatry 1999; 60 (Suppl 21):25-30.
12. Barnes T, Andrews D, Awad AG. Poor compliance with treatment in people with schizophrenia: causes and management. In: Buckley P, Waddington J, editors. Schizophrenia and mood disorders - the new drug therapies in clinical practice. Oxford: Butterworth and Heinemann; 2000. pp. 317-339.
13. Lacro J, Dunn L, Dolder C, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002; 63:892-908. This extensive review, based on articles published since 1980, identifies risk factors for medication non-adherence in patients with schizophrenia.
14. Dolder C, Lacro J, Jeste D. Adherence to antipsychotic and nonpsychiatric medications in middle-aged and older patients with psychotic disorders. Psychosom Med 2003; 65:156-162. This paper provides information about non-psychiatric medications, which are frequently used in elderly psychotic patients treated with antipsychotics, and concludes that non-adherence is as high with non-psychiatric drugs as with psychiatric medications.
15. Arean PA. Cognitive behavioural therapy with older adults. Behav Ther 1993; 17:236-239.
16. Fleischacker WW, Meise U, Gunther V, et al. Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr Scand 1994; 89 (Suppl. 382):511-515.
17. Weiden P, Mott T, Curcio N. Recognition and management of neuroleptic noncompliance. In: Shriqui C, Nasrallah H, editors. Contemporary issues in the treatment of schizophrenia. Washington, DC: American Psychiatric Press; 1995. pp. 411-434.
18. Awad AG, Voruganti LNP, Heslegrave RJ. Assessment of the patient's subjective experiences in acute neuroleptic treatment: implications for compliance and outcome. Int Clin Psychopharmacol 1996; 11 (Suppl 2):55-60.
19. Holzinger A, Löffler W, Miller P, et al. Subjective illness theory and antipsychotic medication compliance by patients with schizophrenia. J Nerv Ment Dis 2002; 190:597-603. In this study, patents' assessment of the helping alliance was identified as the best predictor of compliance.
20. Cramer JA, Rosenheck R. Enhancing medication compliance for people with serious mental illness. J Nerv Ment Dis 1999; 187:53-55.
21. Kemp R, Kirov G, Everitt B, et al. A randomized controlled trial of compliance therapy, 18 months follow-up. Br J Psychiatry 1998; 172:413-419.
22. Perkins D. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002; 63:1121-1128. This paper, based on a search of the literature from 1980 to 2002, provides a comprehensive review of factors leading to non-compliance.
23. Weiss K, Smith T, Hull J, et al. Predictors of risk of nonadherence in outpatients with schizophrenia and other psychotic disorders. Schizophr Bull 2002; 28:341-349. This is an important study that provides data about the time-course of adherence and non-adherence. Patients initially adherent to medications at baseline maintained adherence for an average of 13.3 months. Initially non-adherent patients developed adherence after an average of 5.6 months of treatment.
24. Kampman O, Illi A, Poutanen P, Leinonen E. Four-year outcome in non-compliant schizophrenia patients treated with or without home-based ambulatory outpatient care. Eur Psychiatry 2003; 18:1-5. These authors were able to demonstrate that home visits by a nurse every 2-4 weeks, in addition to maintenance antipsychotic treatment, reduced hospitalization in a subgroup of patients with schizophrenia and who had had several previous hospitalizations.
25. Rosenstock IM. The health belief model and preventive health behaviour. Health Educ Monogr 1974; 2:354-383.
26. Hogan TP, Awad AG, Eastwood MR. A self-report predictive of drug compliance in schizophrenia: reliability and discriminant ability. Psychol Med 1983; 13:177-183.
27. Weiden P, Rapkin B, Mott T, et al. Rating of medications influences (ROMI) scale in schizophrenia. Schizophr Bull 1994; 20:297-310.
28. Naber DA. Self-rating scale to measure subjective effects of neuroleptic drugs; relationship to objective psychopathology, quality of life and other clinical variables. Int Clin Psychopharmacol 1995; 100 (Suppl 3):133-138.
29. Voruganti LNP, Awad AG. Personal evaluation of transitions in treatment (PETiT): a scale to measure subjective aspects of antipsychotic drug therapy in schizophrenia. Schizophr Res 2002; 56:37-46. This is the most recent comprehensive scale for measuring the composite effects of antipsychotic medications, including subjective tolerability, compliance behaviour, cognitive and functional aspects, and aspects of quality of life.
30. Garavan J, Browne S, Gervin M, et al. Compliance with neuroleptic medication in outpatients with schizophrenia: relationship to subjective response to neuroleptics, attitudes to medication and insights. Comp Psychiatry 1998; 39:215-219.
31. Sajatovic M, Rosch D, Sivec H, et al. Insight into illness and attitudes toward medications among inpatients with schizophrenia. Psychiatr Serv 2002; 53:1319-1321. This is an important study that assessed symptoms, severity of illness, functional level and insight into illness in a sample of patients with schizophrenia newly admitted to a state hospital. Antipsychotic treatment improved symptoms, but attitudes towards medication did not change appreciably.
32. Awad AG, Hogan TP, Voruganti LNP, Heslegrave RJ. Patients' subjective experiences on antipsychotic medications: implications for outcome and quality of life. Int Clin Psychopharmacol 1995; 100 (Suppl 3):123-133.
33. Godemann F, Linden M, Gaebel W, et al. Is interval medication a successful treatment regimen for schizophrenic patients with critical attitudes towards treatment? Eur Psychiatry 2003; 18:82-84. This is an important study because of its long follow-up period (2 years) and its prospective design. It clearly demonstrates the absence of any benefit from interval medication treatment for a subgroup of patients with schizophrenia who had had critical negative attitudes to medication at baseline.
34. Nosé M, Barbieri C, Gray R, Tansella M. Clinical interventions for treatment nonadherence in psychosis: meta-analysis. Br J Psychiatry 2003; 183:197-206. This report is one of the very few systematic reviews on interventions designed to improve medication adherence. Although the approach taken in the review is rigorous, the usefulness of any meta-analysis depends upon the quality of the studies entered into the analysis.
35. Zygmunt A, Olfson M, Boyer CA, Mechanic D. Interventions to improve medication adherence in schizophrenia. Am J Psychiatry 2002; 150:1653-1664. This important review of published reports from 1980-2000 concludes that psychoeducational interventions, without accompanying behavioural components and supportive services, are unlikely to be effective in improving medication adherence in schizophrenia.
36. O'Donnell C, Donohoe G, Sharkey N, et al. Compliance therapy: a randomized controlled trial in schizophrenia. BMJ 2003; 327:834-838. This is a well-designed, randomized, controlled study comparing compliance therapy with non-specific counselling: no differences were found at 1 year follow-up. The negative result raises the question of whether 'booster therapy' might be required to maintain positive effects.
37. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 2002; 288:2868-2879. Erratum: JAMA 2003; 289:3242. This is a significant review of several interventions designed to improve adherence to medications in a number of medical conditions, including schizophrenia. It concludes that most of the interventions available are cumbersome, complex and resource-intensive. It confirms the ineffectiveness of psychoeducational approaches, if administered alone.
38. Voruganti LNP, Cortese L, Oyewumi L, et al. Switching from conventional to novel antipsychotic drugs: results of prospective naturalistic study. Schizophr Res 2002; 57:201-208. This report is one of the very few studies to demonstrate better adherence to antipsychotic medications after a switch from first-generation to second-generation antipsychotics; patients were followed up for more than 2 years.
39. Menzin J, Boulanger L, Friedman M, et al. Treatment adherence associated with conventional and atypical antipsychotics in a large state medicaid program. Psychiatr Serv 2003; 54:719-723. This extensive data search of 1 year of medical and pharmacy claims reports that second-generation antipsychotics were associated with significantly less therapy switching (indicating better adherence) than first-generation antipsychotics.
40. Awad AG, Voruganti LNP. Quality of life and new antipsychotics in schizophrenia - are patients better off? Int J Soc Psychiatry 1999; 45:286-291.
41. Steinert T. Which neuroleptic would psychiatrists take for themselves or their relatives? Eur Psychiatry 2003; 18:40-41. A limited survey among psychiatrists indicated that, if they (or a relative) happened to need a neuroleptic drug, they would prefer to take one of the new second-generation antipsychotics.